Protecting Intellectual Property in International Markets

Protecting Intellectual Property in International Markets

Intellectual Property Litigation

Key Contacts


  • Represented Apple in its seven-year global patent war with Samsung that spanned across jurisdictions in Asia, Australia, Europe and the United States. The firm played a critical role in coordinating and executing Apple’s global litigation and regulatory strategy against Samsung. The “Patent Trial of the Century” ended after a jury awarded over $539 million to Apple, who agreed to settle the matter on undisclosed terms and to dismiss all remaining claims.                                                                                                                        
  • Prevailed on behalf of GlaxoSmithKline (GSK), when we obtained a favorable result resolving global litigation with Pfizer, Inc. related to the companies’ competing meningitis B vaccines. We worked closely with GSK’s UK counsel to develop and implement case strategy across multiple jurisdictions so that we took consistent positions in both offensive and defensive actions. We also helped to prepare experts for a UK trial and assisted with European Patent office actions. An undisclosed settlement resolved proceedings in Australia, Austria, Ireland, Italy, the UK, the US, the European Patent Office and the USPTO.
  • Won a major, complete victory for Bristol-Myers Squibb and Pfizer in one of the largest Hatch-Waxman cases ever filed. A district judge found the patents covering our clients’ blockbuster drug Eliquis® were valid and infringed by all generics challenging them. This case covered 25 generic companies and likely protects Eliquis® until at least 2031. This matter involves numerous jurisdictions outside of the US, including Canada, China, Europe, India and Korea. 
  • Representing Genentech in biosimilar patent litigation and related IPRs involving its $7 billion-a-year drug, Herceptin. We have represented Genentech in four district courts and 30 IPR proceedings before the PTAB and have assisted in jurisdictions in the EU, Japan, South Korea and Brazil.
  • Manage the worldwide IP portfolio of Crocs and its subsidiaries, including patent, design, trademark, opposition and support of enforcement actions. Dating back to before its IPO, the firm has routinely advised the company on new product IP clearance matters, IP risk assessment and the ongoing core protection strategy for its most iconic Classic Clog footwear style in jurisdictions around the world.


Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.